ArticleJournal of neurology, neurosurgery, and psychiatry2023
MOG antibody-associated encephalitis in adult: clinical phenotypes and outcomes.
Article in Journal of neurology, neurosurgery, and psychiatry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial.Journal of neurology, neurosurgery, and psychiatry · 2025Trial
- Myelin Oligodendrocyte Glycoprotein Antibody-Associated Cerebral Cortical Encephalitis: A Comparative Study With Antibody-Negative and Non-MOG Antibody-Positive Cortical Encephalitis in Chinese Adults.CNS neuroscience & therapeutics · 2026Article
- Limbic Encephalitis in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease: A Case Report and Literature Review.Internal medicine (Tokyo, Japan) · 2026Review
- Biomarkers for myelin oligodendrocyte glycoprotein-associated disease: recent advances and future.Frontiers in immunology · 2026Review
- Autoimmune encephalitis.Nature reviews. Disease primers · 2025Review
- Neuroimaging spectrum of myelin oligodendrocyte glycoprotein antibody-associated disease with brain involvement: description of various cerebral syndromes.Pediatric radiology · 2025Article
- NMDAR Encephalitis: Identifying Prognostic Biomarkers.Journal of clinical neurology (Seoul, Korea) · 2025Article
- Subgroup analysis of tumefactive demyelinating lesions: clinical, imaging features and outcomes.BMJ neurology open · 2025Article
- Pediatric MOG-Ab-Associated Encephalitis: Supporting Early Recognition and Treatment.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Clinical features of adult patients with positive NMDAR-IgG coexisting with MOG-IgG.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Trigeminal involvement in MOG antibody-associated brainstem encephalitis: a distinct clinico-radiographic presentation.Acta neurologica Belgica · 2024Article
- FLAMES overlaying anti-N-methyl-D-aspartate receptor encephalitis: a case report and literature review.BMC neurology · 2024Review
- Outcome and Sequelae of Autoimmune Encephalitis.Journal of clinical neurology (Seoul, Korea) · 2024Review
- Identifying Key Prognostic Indicators for Relapse and Chronic Epilepsy in Autoimmune Encephalitis: Insights from a Multicenter Retrospective Study.Journal of inflammation research · 2024Article
- Acute haemorrhagic leucoencephalitis as clinical manifestation of MOG antibody-associated disease.Journal of neurology, neurosurgery, and psychiatry · 2023Article
- Myelin oligodendrocyte glycoprotein antibody-associated encephalitis after severe acute respiratory syndrome coronavirus 2 infection: a case report and retrospective case reviews.Encephalitis (Seoul, Korea) · 2023Article
- The MOG antibody associated encephalitis preceded by COVID-19 infection; a case study and systematic review of the literature.Frontiers in neurology · 2023Article
- Seizures as the initial manifestation: characterizing the adult phenotype of MOG antibody-associated disease.Frontiers in neurologyArticle
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe investigated the clinical characteristics and outcomes of myelin oligodendrocyte glycoprotein (MOG) antibody-associated autoimmune encephalitis (MOGAE) in adult patients.
methodsFrom an institutional cohort, we analysed adult patients with MOGAE followed-up for more than 1 year. Disease severity was assessed using the modified Rankin scale (mRS) and Clinical Assessment Scale in Autoimmune Encephalitis scores. Immunotherapy profiles, outcomes and disease relapses were evaluated along with serial brain MRI data.
resultsA total of 40 patients were enrolled and categorised into cortical encephalitis (18 patients), limbic encephalitis (LE, 5 patients) and acute disseminated encephalomyelitis (ADEM, 17 patients). 80.0% of patients achieved good clinical outcomes (mRS 0‒2) and 40.0% relapsed. The LE subtype was associated with an older onset age (p=0.004) and poor clinical outcomes (p=0.014) than the other subtypes but with a low rate of relapse (0.0%). 21/25 (84.0%) relapse attacks were associated with an absence or short (≤6 months) immunotherapy maintenance. On MRI, the development of either diffuse cerebral or medial temporal atrophy within the first 6 month was correlated with poor outcomes. MOG-antibody (MOG-Ab) was copresent with anti-N-methyl-D-aspartate receptor (NMDAR)-antibody in 13 patients, in whom atypical clinical presentation (cortical encephalitis or ADEM, p
conclusionsOutcomes are different according to the three phenotypes in MOGAE. Short immunotherapy maintenance is associated with relapse, and brain atrophy was associated with poor outcomes. Patients with dual antibodies of NMDAR and MOG have a high relapse rate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.